Tokyo Tape
Sign in
← Sumitomo Chemical

Quarterly report · Q1

4005.TEDINET S100RJX5
Period2023-04-01 → 2023-06-30
Filed2023-08-08
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥563.1bn2023-04-01 → 2023-06-30Cons.Revenue IFRS
Revenue¥2.90T2022-04-01 → 2023-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥774.1bn2022-04-01 → 2022-06-30Cons.Revenue IFRS
Operating income−¥71.7bn2023-04-01 → 2023-06-30Cons.Operating profit loss IFRS
Operating income¥66.3bn2022-04-01 → 2022-06-30Cons.Operating profit loss IFRS
Profit before tax−¥49.9bn2023-04-01 → 2023-06-30Cons.Profit loss before tax IFRS
Profit before tax¥231m2022-04-01 → 2023-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥113.7bn2022-04-01 → 2022-06-30Cons.Profit loss before tax IFRS
Net income (owners)−¥33.2bn2023-04-01 → 2023-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥7.0bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥70.0bn2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent IFRS
Net income−¥51.2bn2023-04-01 → 2023-06-30Cons.Profit loss IFRS
Net income−¥46.9bn2022-04-01 → 2023-03-31Cons.Profit loss IFRS (5-year summary)
Net income¥85.1bn2022-04-01 → 2022-06-30Cons.Profit loss IFRS
Total assets¥4.37Tat 2023-06-30Cons.Assets IFRS
Total assets¥4.17Tat 2023-03-31Cons.Assets IFRS
Total assets¥4.67Tat 2022-06-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥2.82Tat 2023-06-30Cons.Liabilities IFRS
Total liabilities¥2.68Tat 2023-03-31Cons.Liabilities IFRS
Net assets / equity¥1.55Tat 2023-06-30Cons.Equity IFRS
Net assets / equity¥1.49Tat 2023-03-31Cons.Equity IFRS
Net assets / equity¥1.86Tat 2022-06-30Cons.Equity IFRS
Net assets / equity¥1.70Tat 2022-03-31dCons.Equity IFRS
Equity (owners)¥1.22Tat 2023-06-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.17Tat 2023-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.34Tat 2022-06-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥323.1bnat 2023-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥305.8bnat 2023-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥498.6bnat 2022-06-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥365.4bnat 2022-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow−¥131.9bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥111.6bn2022-04-01 → 2023-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥42.6bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥13.4bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥19.4bn2022-04-01 → 2023-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow¥46.0bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow¥142.0bn2023-04-01 → 2023-06-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥178.5bn2022-04-01 → 2023-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow¥11.5bn2022-04-01 → 2022-06-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥-20.272023-04-01 → 2023-06-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥4.272022-04-01 → 2023-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥42.812022-04-01 → 2022-06-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥4.272022-04-01 → 2023-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
Equity ratio28.0%at 2023-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.1%at 2023-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio28.8%at 2022-06-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-06-30¥37.4bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-06-30¥17.3bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-06-30¥20.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-06-30¥2.4bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-06-30−¥27.9bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-06-30−¥27.9bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-06-30−¥4.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2023-04-01 → 2023-06-30¥78.8bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2023-04-01 → 2023-06-30¥73.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥5.5bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2023-04-01 → 2023-06-30¥3.0bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2023-04-01 → 2023-06-30¥193.7bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2023-04-01 → 2023-06-30¥192.4bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1.4bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥21.0bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2023-04-01 → 2023-06-30¥103.5bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2023-04-01 → 2023-06-30¥102.7bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥762m
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2023-04-01 → 2023-06-30−¥7.0bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2023-04-01 → 2023-06-30¥94.6bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2023-04-01 → 2023-06-30¥94.5bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥110m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2023-04-01 → 2023-06-30¥6.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2023-04-01 → 2023-06-30¥83.0bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2023-04-01 → 2023-06-30¥83.0bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2023-04-01 → 2023-06-30¥1m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2023-04-01 → 2023-06-30−¥33.3bn
—segment totalrevenue2023-04-01 → 2023-06-30¥553.6bn
—segment totalrevenue external2023-04-01 → 2023-06-30¥545.9bn
—segment totalrevenue intersegment2023-04-01 → 2023-06-30¥7.7bn
—segment totalsegment profit2023-04-01 → 2023-06-30−¥51.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-06-30¥31.7bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-06-30¥14.2bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-06-30¥17.5bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-06-30¥3.3bn
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥24.8bn
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥7.5bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue2022-04-01 → 2022-06-30¥91.3bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue external2022-04-01 → 2022-06-30¥86.4bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥4.8bn
jpcrp040300-q1r_E00752-000Energy And Functional Materialsreportable segmentsegment profit2022-04-01 → 2022-06-30¥6.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue2022-04-01 → 2022-06-30¥240.0bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue external2022-04-01 → 2022-06-30¥238.6bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥1.5bn
jpcrp040300-q1r_E00752-000Essential Chemicals And Plasticsreportable segmentsegment profit2022-04-01 → 2022-06-30¥10.0bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue2022-04-01 → 2022-06-30¥153.5bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue external2022-04-01 → 2022-06-30¥152.6bn
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥945m
jpcrp040300-q1r_E00752-000Health And Agriculture Relatedreportable segmentsegment profit2022-04-01 → 2022-06-30¥21.9bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue2022-04-01 → 2022-06-30¥114.8bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue external2022-04-01 → 2022-06-30¥114.7bn
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥116m
jpcrp040300-q1r_E00752-000Information Electronic Chemistryreportable segmentsegment profit2022-04-01 → 2022-06-30¥15.8bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue external2022-04-01 → 2022-06-30¥167.7bn
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E00752-000Medical Productsreportable segmentsegment profit2022-04-01 → 2022-06-30¥14.1bn
—segment totalrevenue2022-04-01 → 2022-06-30¥767.3bn
—segment totalrevenue external2022-04-01 → 2022-06-30¥759.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥7.4bn
—segment totalsegment profit2022-04-01 → 2022-06-30¥68.4bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 840
ItemContextValueUnit
Provisions ncl IFRSPrior1YearInstant38443000000JPY
Provisions ncl IFRSCurrentQuarterInstant39825000000JPY
Deferred tax liabilities IFRSPrior1YearInstant101164000000JPY
Deferred tax liabilities IFRSCurrentQuarterInstant118497000000JPY
Other non current liabilities ncl IFRSPrior1YearInstant68856000000JPY
Other non current liabilities ncl IFRSCurrentQuarterInstant60679000000JPY
Non current labilities IFRSPrior1YearInstant1397947000000JPY
Non current labilities IFRSCurrentQuarterInstant1391691000000JPY
Liabilities IFRSPrior1YearInstant2676314000000JPY
Liabilities IFRSCurrentQuarterInstant2823859000000JPY
Share capital IFRSPrior1YearInstant89810000000JPY
Share capital IFRSCurrentQuarterInstant89810000000JPY
Capital surplus IFRSPrior1YearInstant－JPY
Capital surplus IFRSCurrentQuarterInstant0JPY
Retained earnings IFRSPrior1YearInstant891552000000JPY
Retained earnings IFRSCurrentQuarterInstant854302000000JPY
Treasury shares IFRSPrior1YearInstant-8349000000JPY
Treasury shares IFRSCurrentQuarterInstant-8350000000JPY
Other components of equity IFRSPrior1YearInstant197830000000JPY
Other components of equity IFRSCurrentQuarterInstant289039000000JPY
Other comprehensive income related to assets held for sale IFRSPrior1YearInstant349000000JPY
Other comprehensive income related to assets held for sale IFRSCurrentQuarterInstant－JPY
Equity attributable to owners of parent IFRSPrior1YearInstant1171192000000JPY
Equity attributable to owners of parent IFRSCurrentQuarterInstant1224801000000JPY
Non controlling interests IFRSPrior1YearInstant317997000000JPY
Non controlling interests IFRSCurrentQuarterInstant325138000000JPY
Equity IFRSPrior1YearInstant1489189000000JPY
Equity IFRSCurrentQuarterInstant1549939000000JPY
Liabilities and equity IFRSPrior1YearInstant4165503000000JPY
Liabilities and equity IFRSCurrentQuarterInstant4373798000000JPY
Revenue IFRSPrior1YTDDuration774134000000JPY
Revenue IFRSCurrentYTDDuration563143000000JPY
Cost of sales IFRSPrior1YTDDuration528345000000JPY
Cost of sales IFRSCurrentYTDDuration434011000000JPY
Gross profit IFRSPrior1YTDDuration245789000000JPY
Gross profit IFRSCurrentYTDDuration129132000000JPY
Selling general and administrative expenses IFRSPrior1YTDDuration195980000000JPY
Selling general and administrative expenses IFRSCurrentYTDDuration178072000000JPY
Other operating income IFRSPrior1YTDDuration8181000000JPY
Other operating income IFRSCurrentYTDDuration10135000000JPY
Other operating expenses IFRSPrior1YTDDuration4379000000JPY
Other operating expenses IFRSCurrentYTDDuration20900000000JPY
Share of profit loss of investments accounted for using equity method IFRSPrior1YTDDuration12671000000JPY
Share of profit loss of investments accounted for using equity method IFRSCurrentYTDDuration-12042000000JPY
Operating profit loss IFRSPrior1YTDDuration66282000000JPY
Operating profit loss IFRSCurrentYTDDuration-71747000000JPY
Finance income IFRSPrior1YTDDuration61908000000JPY
Finance income IFRSCurrentYTDDuration39171000000JPY
Finance costs IFRSPrior1YTDDuration14534000000JPY
Finance costs IFRSCurrentYTDDuration17286000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2023-03-31pass
balance sheet identityconsolidated 2023-06-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-06-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-06-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-06-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-06-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-06-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-06-30pass